Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea 082800
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America VNRX
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America VYNE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan 4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America WVE
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea 010600
Werewolf Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
United States of America HOWL
WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea 016580
Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America WHWK

Talk to a Data Expert

Have a question? We'll get back to you promptly.